Certolizumab
- CAS No.
- 428863-50-7
- Chemical Name:
- Certolizumab
- Synonyms
- CERTOLIZUMAB PEGOL;Cimzia;Cdp870;Pha 738144;Unii-umd07X179e;Research Grade Certolizumab;Research Grade Certolizumab(DHB94401);(2S)-1-((2S)-6-aMino-2-((hydroxy(4-phenylbutyl)phosphoryl)oxy)hexanoyl)pyrrolidine-2-carboxylic acid;Immunoglobulin, anti-(human tumor necrosis factor alpha) fab' fragment (human-mouse monoclonal cdp870 heavy chain), disulfide with human-mouse monoclonal cdp870 light chain, pegylated
- CBNumber:
- CB52497315
- Molecular Formula:
- C24H22F3N
- Molecular Weight:
- 381.4333896
- MDL Number:
- MOL File:
- 428863-50-7.mol
- MSDS File:
- SDS
- TDS File:
- TDS
| storage temp. | Store at -20°C |
|---|---|
| form | Liquid |
| color | Colorless to light yellow |
| FDA UNII | UMD07X179E |
| NCI Drug Dictionary | certolizumab pegol |
| ATC code | L04AB05 |
SAFETY
Risk and Safety Statements
| Hazardous Substances Data | 428863-50-7(Hazardous Substances Data) |
|---|
Certolizumab price
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| ChemScene | CS-0031125 | Certolizumab pegol 99.30% | 428863-50-7 | 1mg | $195 | 2026-06-04 | Buy |
| ChemScene | CS-0031125 | Certolizumab pegol 99.30% | 428863-50-7 | 5mg | $412 | 2026-06-04 | Buy |
| ChemScene | CS-0031125 | Certolizumab pegol 99.30% | 428863-50-7 | 10mg | $650 | 2026-06-04 | Buy |
| Arctom | SLK-A2798 | Certolizumab (Anti-TNFSF2 / TNFa) 99% | 428863-50-7 | 1mg | $257 | 2026-05-26 | Buy |
| Arctom | SLK-A2798 | Certolizumab (Anti-TNFSF2 / TNFa) 99% | 428863-50-7 | 1mg*5 | $751 | 2026-05-26 | Buy |
Certolizumab Chemical Properties,Uses,Production
Description
Certolizumab pegol, a tumor necrosis factor α(TNF-α) blocker, was launched for the treatment of moderate-to-severe Crohn’s disease. It is specifically indicated for reducing signs and symptoms and maintaining clinical response in adult patients who have had an inadequate response to conventional therapy. Certolizumab pegol is the third anti-TNF-α biologic to be marketed for this indication behind infliximab (Remicade) and adalimumab (Humira). Certolizumab pegol is a recombinant, humanized antibody Fab’ fragment linked to approximately 40 kDa polyethylene glycol (PEG). The Fab’ fragment is composed of a light chain with 214 amino acids and a heavy chain with 229 amino acids. It is manufactured in E.coli and is subsequently subjected to purification and conjugation to PEG, to generate certolizumab pegol. The addition of PEG moiety significantly enhances the plasma half-life of the antibody, allowing for less frequent dosing. Certolizumab pegol neutralizes both soluble and membrane-associated forms of human TNF-a. It binds to human TNF-a with slightly higher affinity (KD 0.09 nM) than infliximab (KD 0.23 nM) and adalimumab (KD 0.16 nM). In addition, in cellular assays, certolizumab pegol is more potent in preventing TNF-a-induced killing of L929 fibroblasts than infliximab and adalimumab (IC50 0.35 ng/mL versus 5 and 6 ng/mL, 592 Shridhar Hegde and Michelle Schmidt respectively).
Originator
UCB Celltech (United Kingdom)
Uses
Certolizumab pegol increases nonexudative age-related macular degeneration diagnosis among medicare beneficiaries with rheumatoid arthritis.
Uses
Treatment of rheumatoid arthritis and inflammatory bowel disease.
brand name
Cimzia
Side effects
The most common adverse reactions with certolizumab were upper respiratory infections (20%), urinary tract infections (7%), and anthralgias (6%). TNF-a blockers as a class have been linked to increased risk of opportunistic infections and malignancy. Tuberculosis, invasive fungal infections, and other serious infections have occurred in patients receiving certolizumab pegol, and the drug label contains a black-box warning of the risk.
Drug interactions
Potentially hazardous interactions with other drugs
Anakinra and abatacept: avoid concomitant use.
Live vaccines: avoid concomitant use.
Metabolism
The Fab fragment comprises protein compounds and is expected to be degraded to peptides and amino acids by proteolysis. The de-conjugated PEG component is rapidly eliminated from plasma and is to an unknown extent excreted renally.
Certolizumab Preparation Products And Raw materials
Raw materials
Preparation Products
Certolizumab Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| shanghai cooperpharm co.,LTD . | +86-021-58975553 | sales@cooperpharm.com | China | 1210 | 56 |
| Shanghai Han-Xiang Chemical Co., Ltd. | 17754423994 | candy@biochempartner.com | China | 3057 | 58 |
| BOC Sciences | 16314854226; +8616314854226 | inquiry@bocsci.com | United States | 19852 | 58 |
| TargetMol Chemicals Inc. | +1-781-999-5354; +1-00000000000 | marketing@targetmol.com | United States | 32431 | 58 |
| Wuhan Chemstan Biotechnology Co., Ltd. | 027-65317797 15926423062 | 422450190@qq.com | China | 10305 | 58 |
| Beijing Jin Ming Biotechnology Co., Ltd. | 010-60605840 | psaitong@jm-bio.com | China | 27626 | 58 |
| TargetMol Chemicals Inc. | 4008200310 15002144251 | marketing@tsbiochem.com | China | 24951 | 58 |
| Biolab Reagents | 027-65279366 18108604356 | products@biolabreagent.com | China | 9864 | 58 |
| Shanghai Yifei Biotechnology Co. , Ltd. | 021-65675885 18964387627 | customer_service@efebio.com | China | 11963 | 58 |
| Wuhan Acumen Bio-Technology Co.,ltd | 027-027-16602739303 16602739303 | 673003916@qq.com | China | 4593 | 58 |
View Lastest Price from Certolizumab manufacturers
| Image | Update time | Product | Price | Min. Order | Purity | Supply Ability | Manufacturer | |
|---|---|---|---|---|---|---|---|---|
 |
2026-07-27 | Certolizumab pegol
428863-50-7
|
$147.00-496.00 | 99.00% | 10g | TargetMol Chemicals Inc. |
-
- Certolizumab pegol
428863-50-7
- $147.00-496.00
- 99.00%
- TargetMol Chemicals Inc.
